+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer

Gynecologic Oncology 2019

The benefit of adjuvant chemotherapy for FIGO stage I, high-grade serous ovarian cancer (HGSOC) after optimal staging is a matter of debate. We investigated the effect of adjuvant chemotherapy on recurrence-free survival (RFS) and overall survival (OS) in a population-based cohort study. All patients diagnosed in the Netherlands between 2002 and 2014 with FIGO stage I HGSOC who underwent surgical staging were included. Data on clinical characteristics, histopathology, completeness of staging and survival were collected from the Netherlands Cancer Registry and Dutch Pathology Registry. Recurrence data was collected from hospital files. We used Kaplan-Meier methods to estimate RFS and OS and Cox-proportional hazard analyses to control for differences in baseline characteristics between patients who did or did not receive chemotherapy. We identified 223 patients who underwent optimal staging procedures including lymph node sampling. Events of disease recurrence occurred in 21 of the 101 patients (21%) who received adjuvant chemotherapy and in 46 of the 122 patients (38%) who did not (multivariable hazard ratio (HR), 0.37; 95%CI 0.22-0.64; p < 0.01). Five-year RFS was 81% after staging plus chemotherapy and 59% after staging only. At a median follow-up of 105 months, 21 patients (21%) in the chemotherapy group and 38 patients (31%) in the no-chemotherapy group had died (multivariable HR 0.50; 95%CI 0.28-0.89; p = 0.02). Ten-year OS was 78% with chemotherapy and 62% without chemotherapy. Adjuvant chemotherapy improves long-term RFS and OS in patients with FIGO stage I HGSOC after optimal staging.

(PDF emailed within 0-6 h: $19.90)

Accession: 066657997

Download citation: RISBibTeXText

PMID: 30948193

DOI: 10.1016/j.ygyno.2019.03.257

Related references

Adjuvant chemotherapy beneficial for select early-stage, low-grade serous ovarian cancer patients. Gynecologic Oncology 141: 187-188, 2016

Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia. Open Access Macedonian Journal of Medical Sciences 5(7): 904-908, 2018

Involuntary weight loss between surgery and chemotherapy impairs overall survival of high-grade serous ovarian cancer patients. Gynecologic Oncology 141: 97-98, 2016

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. Journal of Ovarian Research 12(1): 40, 2019

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy. Gynecologic Oncology 149(1): 155-162, 2018

Identification of a gene signature that can predict lone-term survival in patients with high-grade late stage serous ovarian cancer. Journal of Clinical Oncology 23(16_suppl): 5032-5032, 2016

Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage. International Journal of Gynecological Pathology 37(4): 324-330, 2017

No survival benefit with adjuvant chemotherapy in nonserous stage IB grade 2 epithelial ovarian cancer. Gynecologic Oncology 141: 53-54, 2016

Survival impact of complete cytoreductive surgery in the primary management of FIGO stage IIIC, high-grade, epithelial ovarian cancer. Journal of Clinical Oncology 26(15_suppl): 16551-16551, 2016

The prognostic significance of residual diseases, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecologic Oncology 56(2): 175-180, 1995

The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer. Archives of Gynecology and Obstetrics 295(2): 451-458, 2016

Surgical Stage I high-grade ovarian cancer: is adjuvant chemotherapy warranted?. European Journal of Gynaecological Oncology 36(6): 633-636, 2016

Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Annals of Oncology 27(4): 625-634, 2016

Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience. Yonsei Medical Journal 59(8): 930-936, 2018

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. Journal of Ovarian Research 9(1): 85, 2017